- Scott Thomson has been appointed as the new CEO of Actylis.
- Thomson brings three decades of experience in the pharmaceutical and chemical industries.
Actylis, a global manufacturer and sourcing expert of critical materials and performance ingredients for the life sciences and specialty chemicals markets, has appointed Scott Thomson as Chief Executive Officer.
Thomson, who has a thirty-year track record in the pharmaceutical and chemical industries, steps into his new role following his tenure as CEO of SPI Pharma. At SPI Pharma, he led the sustainable improvement of the company’s strategic development and execution. His experience also includes senior executive roles at BASF, where he was responsible for several global life science and specialty ingredients businesses.
“Scott has an impressive tenure of driving long-term growth, and we look forward to welcoming Scott as we bring our client-centric, flexible customer service model and extensive product offerings to an increasing number of geographies, customers and applications,” said Rakesh Sachdev, Chairman of Actylis.
Thomson expressed enthusiasm about his new position, stating, “I feel privileged to lead the Actylis team at this exciting juncture, and I look forward to partnering with our customers, Actylis’ management and employees, and New Mountain to grow and further develop Actylis’ offerings. There is significant opportunity to accelerate the company’s growth and I look forward to building upon the company’s achievements to date both organically and inorganically.”
The appointment aims to bolster Actylis’ strategic development and expand its reach in the global market. Thomson’s extensive experience in the industry is expected to enhance Actylis’ growth and service offerings, making a positive impact on the company’s future trajectory.
Overview of outsourcing trends 
